Slide 1: Investor Presentation: Interim Financial Results
For personal use only INVESTOR PRESENTATION Interim Financial Results Half year ended 31 December 2024 19 February 2025
Slide 2: Disclaimer
DISCLAIMER The information in this presentation was prepared by EBOS Group Limited (“EBOS” or the “Group”) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and, to the extent permitted by law, no representation is made as to
Slide 3: Key Highlights
KEY HIGHLIGHTS For personal use only Strategy execution driving strong revenue growth (ex. CWA1) Benefits from efficiency and cost management Strong cash generation and dividend maintained Disciplined capital allocation and strategic investments to support future growth First Pharmacy Wholesale Agre
Slide 4: Financial Summary
FINANCIAL SUMMARY EBOS reports strong underlying growth (ex. CWA1) reflecting the strength of its diversified business model and reiterates guidance that the Group expects to generate Underlying EBITDA between $575 – 600 million in FY25 For personal use only Revenue Underlying EBITDA Underlying EPS
Slide 5: Group Performance
GROUP PERFORMANCE The Group delivered strong revenue growth of 9.5% and Underlying EBITDA growth of 7.1% (ex. CWA1) Var% ex • Revenue increased by $519m or 9.5% (ex CWA1) with: $m H1 FY25 H1 FY24 Var Var% For personal use only 1 CWA Underlying Results 2 o Healthcare up $501m or 9.7%1 Revenue 5,991 6
Slide 6: Long Term Growth
LONG TERM GROWTH EBOS has delivered consistent year-on-year GOR growth over the last decade, excluding the CWA contract For personal use only GOR – first half period ($m) Well positioned to deliver long-term growth • Defensive growth sectors 799 • Scale and leading positions • Diversified group • Mu
Slide 7: Near-Term Growth Strategy
NEAR-TERM GROWTH STRATEGY Strong progress has been made on the near-term strategy with all initiatives tracking at or above expectations For personal use only Growth sources Objective Status update Progress 1 • Healthcare and Animal Care Base business segments to record positive On Underlying EBITDA
Slide 8: Investing for Growth
INVESTING FOR GROWTH Consistent with the strategy of growing in Southeast Asia, EBOS completed two bolt-on acquisitions and increased its stake in Transmedic to 100% For personal use only Attractive dynamics of Southeast Asia healthcare Investments completed Three investments completed1 • Large and
Slide 9: Division Highlights
DIVISION HIGHLIGHTS Community Pharmacy Institutional Contract Logistics Animal Care Healthcare For personal use only • First Pharmaceutical • Continued high growth • Strong organic growth in • Black Hawk and Vitapet Wholesaler Agreement in hospital medicines Australia underpinned by continued to exp
Slide 10: Division and Segment Performance
DIVISION AND SEGMENT PERFORMANCE Both the Healthcare and Animal Care segments recorded strong GOR and EBITDA growth (ex. CWA1) For personal use only GOR bridge ($m) Underlying EBITDA bridge ($m) H1 FY25 H1 FY25 growth 4.6% 8.3% 0.9% 12.2% 6.7% growth 7.0% 7.2% -6.1% 7.1% vs. pcp1 vs. pcp1 (1) 1 11 4
Slide 11: Sustainability Snapshot
SUSTAINABILITY SNAPSHOT For personal use only 11
Slide 12: Results: Healthcare
12 For personal use only RESULTS HEALTHCARE
Slide 13: Healthcare Segment
HEALTHCARE SEGMENT The Healthcare segment’s strong underlying performance (ex. CWA1) was driven by organic growth Var% ex • Strong performances across the Community Pharmacy (ex. $m H1 FY25 H1 FY24 Var Var% CWA1 CWA1), TerryWhite Chemmart (TWC) and Institutional For personal use only Revenue 5,687 6
Slide 14: Community Pharmacy
COMMUNITY PHARMACY • Revenue increased by 12.2% and GOR increased by 4.6% (ex. Var% ex $m H1 FY25 H1 FY24 Var Var% CWA1), driven by: CWA1 For personal use only Revenue 3,144 3,912 (768) (19.6%) 12.2% o Pharmacy wholesale revenue wins from new customers of approximately $100m in H1 FY25 ($450m+ annua
Slide 15: TerryWhite Chemmart
TerryWhite Chemmart that’s real chemistry Network sales growth in H1 FY25 For personal use only • TerryWhite Chemmart (TWC) added 24 net new partners to its national network in H1 FY25, continuing its impressive growth in pharmacy numbers and growing to 616 stores (+52 in the last year) Total sales
Slide 16: Institutional Healthcare
INSTITUTIONAL HEALTHCARE • Institutional Healthcare revenue increased by $191m (9.7%) $m H1 FY25 H1 FY24 Var Var% and GOR increased by $25m (8.3%) For personal use only Revenue 2,157 1,966 191 9.7% • Medicines and consumables revenue grew by 10.5%, driven by: - Medicines, consumables 1,856 1,680 176
Slide 17: Contract Logistics
CONTRACT LOGISTICS • Contract Logistics GOR in H1 FY25 was in line with the prior $m H1 FY25 H1 FY24 Var Var% corresponding period: For personal use only GOR1 75 75 1 0.9% o Australia performed strongly with GOR growth of 16.4% driven by new and existing principals, enabled by the investment in new
Slide 18: Results: Animal Care
18 For personal use only CARE ANIMAL RESULTS
Slide 19: Animal Care Segment
ANIMAL CARE SEGMENT The Animal Care segment delivered revenue and Underlying EBITDA growth driven by strong performance from our branded business, including continued new product development For personal use only $m H1 FY25 H1 FY24 Var Var% • Animal Care revenue increased by $18m (6.3%) and Underlyi
Slide 20: Product and Brand Update
PRODUCT AND BRAND UPDATE The branded business’ strong performance was supported by new product launches in 2024 that expanded our categories. Additional category expansion is planned For personal use only Black Hawk dog food category expansion Vitapet dry dog food category expansion • Black Hawk’s p
Slide 21: Financial Information
For personal use only FINANCIAL INFORMATION 21
Slide 22: Cash Flow
CASH FLOW The Group generated strong cash flows with Underlying Cash from Operating Activities up $90m $m H1 FY25 H1 FY24 Var$ Var% Underlying Cash from Operating For personal use only Activities ($m)1 Underlying EBITDA 291 313 (22) (7.1%) Net interest paid (51) (45) (7) H1 H2 405 367 Tax (paid) (39
Slide 23: Working Capital and ROCE
WORKING CAPITAL AND ROCE Net working capital improved by $89m, benefitting from the conclusion of the CWA contract, and ROCE (ex. CWA1) increased by 10bp For personal use only Working Capital Return on Capital Employed $m H1 FY25 H1 FY24 Var$ Net Working Capital Trade & other receivables 1,424 1,527
Slide 24: Net Debt and Maturity Profile
NET DEBT AND MATURITY PROFILE EBOS refinanced its corporate debt facilities, increasing available funds and extending debt maturity For personal use only Net Debt and Leverage ratio1 Debt Maturity Profile 750 2.06x 2.07x 700 1.76x 1.89x 1.52x 550 390 750 350 1,088 1,019 1,065 838 767 136 57 310 5 20
Slide 25: Costs and Cost Reduction Initiatives
COSTS AND COST REDUCTION INITIATIVES The Group continues to focus on efficiencies and cost management For personal use only • Consistent with the Group’s near-term strategy, cost reduction initiatives have continued to be a focus • Cost savings of $15 million were achieved in H1 FY25 and we continue
Slide 26: Earnings and Dividends per Share
EARNINGS AND DIVIDENDS PER SHARE The Group delivered Underlying EPS of 67.5 cps and maintained its interim dividend at H1 FY24 level Underlying Earnings per Share (cents) Dividends per Share (NZ cents) For personal use only H1 H2 157.9 H1 H2 147.9 118.5 110.0 129.5 96.0 114.9 88.5 78.4 73.3 61.5 57.
Slide 27: Growth Strategy and Outlook
For personal use only GROWTH STRATEGY AND OUTLOOK 27
Slide 28: Group Strategy
GROUP STRATEGY For personal use only Deliver long-term sustainable growth and shareholder returns via… Organic growth M&A Core business growth Operational excellence Strategic acquisitions ✓ Revenue growth through customer and ✓ Investment in distribution and ✓ Strengthen core businesses pricing str
Slide 29: Outlook and FY25 Guidance Reaffirmed
OUTLOOK AND FY25 GUIDANCE REAFFIRMED EBOS reiterates its guidance that the Group expects to generate Underlying EBITDA between $575 – 600 million in FY25 Underlying EBITDA ($m) For personal use only • EBOS is pleased with the strong underlying 624 earnings growth (ex. CWA1) achieved in H1 FY25, 600
Slide 30: Supporting Information
For personal use only SUPPORTING INFORMATION 30
Slide 31: Reconciliation of Statutory to Underlying Results
RECONCILIATION OF STATUTORY TO UNDERLYING RESULTS For personal use only H1 FY25 H1 FY24 $m Revenue EBITDA EBIT PBT NPAT Revenue EBITDA EBIT PBT NPAT Statutory result 5,991 276 207 156 110 6,582 303 237 192 136 M&A transaction costs - 5 5 5 4 - 10 10 10 7 Restructuring & site transition costs - 10 10
Slide 32: Segment EBITDA and EBIT Reconciliation
SEGMENT EBITDA AND EBIT RECONCILIATION EBITDA EBIT $m H1 FY25 H1 FY24 Var$ Var% H1 FY25 H1 FY24 Var$ Var% Healthcare For personal use only Statutory 235 274 (38) (14.0%) 173 213 (40) (18.8%) add M&A transaction costs 5 2 4 5 2 4 add Restructuring & site transition costs 10 - 10 10 - 10 add LifeHealt
Slide 33: Glossary of Terms and Measures
GLOSSARY OF TERMS AND MEASURES Except where noted, common terms and measures used in this document are based upon the following definitions: Term Definition Revenue Revenue from the sale of goods and the rendering of services For personal use only Gross Operating Revenue (GOR) Revenue less cost of s
Slide 34: www.ebosgroup.com
For personal use only www.ebosgroup.com